Mitochondria host key metabolic processes vital for cellular energy provision and are central to cell fate decisions. They are subjected to unique genetic control by both nuclear DNA and their own multi-copy genome - mitochondrial DNA (mtDNA). Mutations in mtDNA often lead to clinically heterogeneous, maternally inherited diseases that display different organ-specific presentation at any stage of life. For a long time, genetic manipulation of mammalian mtDNA has posed a major challenge, impeding our ability to understand the basic mitochondrial biology and mechanisms underpinning mitochondrial disease. However, an important new tool for mtDNA mutagenesis has emerged recently, namely double-stranded DNA deaminase (DddA)-derived cytosine base editor (DdCBE). Here, we test this emerging tool for in vivo use, by delivering DdCBEs into mouse heart using adeno-associated virus (AAV) vectors and show that it can install desired mtDNA edits in adult and neonatal mice. This work provides proof-of-concept for use of DdCBEs to mutagenize mtDNA in vivo in post-mitotic tissues and provides crucial insights into potential translation to human somatic gene correction therapies to treat primary mitochondrial disease phenotypes.
Mitochondria play a central role in energy provision to the cell and in several key metabolic pathways, such as thermogenesis, calcium handling, iron-sulfur cluster biogenesis, and apoptosis.1,2 Mitochondria produce energy in the form of ATP, which is synthesized in the process of oxidative phosphorylation (OXPHOS), involving sequential redox reactions coupled with proton pumping performed by mitochondrial membrane-embedded respiratory chain complexes (I–IV) and ATP synthase (complex V). In mammals, the mitochondrial proteome comprises ~1200 proteins, with most of them being nuclear DNA (nDNA)-encoded. However, 13 essential OXPHOS polypeptides, and 22 tRNAs, and 2 rRNAs required for their translation reside inside the mitochondrial matrix, encoded by the mitochondrial DNA (mtDNA)—a 16.5 kb, maternally inherited multicopy circular genome.

Mitochondrial diseases are genetic disorders, caused by mutations, either in nDNA or mtDNA, that lead to mitochondrial energy production impairment and perturbations in other aspects of cellular homeostasis. With a prevalence of ~23 in 100,000, mitochondrial disorders are among the most common inherited diseases, and are often associated with severe disability and shortened lifespan.4 There are currently no effective treatments for these disorders and clinical management focuses on treating complications.5 Mutations in mtDNA and mitochondrial dysfunction have also been implicated in many common diseases with high societal impact and ageing.6,7 Mammalian cells can contain 100–1000 s copies of mtDNA.8 Pathogenic variants in mtDNA can either be present in all copies (homoplasmy) or only in a portion of genomes (heteroplasmy), with mutant load varying across cells, tissues, and organs.9 In heteroplasmy, the mutant load required for clinical expression must exceed a threshold, which is highly variable and is dependent on the mtDNA variant, affected tissues/organ(s), and genetic/environmental contexts, but is usually more than 60%.10

Despite the ongoing genome-engineering revolution enabled by the CRISPR/Cas-based systems, mammalian mtDNA has been resistant to genetic modifications, in a large part owing to ineffective nucleic acid import into the mitochondria.11 The inability to edit mtDNA sequences in mammalian mitochondria within cells has hampered the research of normal mtDNA processes, the development of in vivo models and therapies for mtDNA diseases. For many years the approaches towards manipulation of mtDNA in mammals have been mainly limited to mitochondrial targeted restriction enzymes.12–14 and programmable nucleases.15–21 These nucleases have been used to eliminate undesired mtDNA molecules from heteroplasmic populations, to move the mutant mtDNA heteroplasmy below the pathogenicity threshold.22 Following extensive trials in vitro, the mitochondrial nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept. Delivered by adeno-associated virus (AAV) in heteroplasmic mouse models, mtRE, mtZFN, mitoTALEN, or nuclease-based approaches have reached in vivo proof-of-concept.

While programmable nucleases have proven useful in changing the existing heteroplasm, they are unable to introduce novel mtDNA variants. However, recently a novel tool has emerged: DdDA-derived cytosine base editor (DdCBE), which catalyzes site-specific C:G to T:A conversions in mtDNA with good target specificity in human cultured cells.28 DdCBE is based upon a modified bacterial toxin DdDAox (separated, non-toxic halves fused to TALE proteins) which is targeted to the mitochondrial matrix to catalyze the deamination of cytidines within dsDNA at sequence determined by TALE design.28 Current DdCBEs deaminate cytidines (in the TC:GA sequence context) to uracil leading to a GC:AT > TC:GA > TT:AA mutations upon subsequent replication.28 An initial proof-of-concept of successful installment of mtDNA edits by delivering DdCBEs mRNA into embryos in the mouse has also recently been provided.29 In this study, we provide proof-of-concept for the use of DdCBEs in vivo in somatic tissue. We used the mouse heart as a surrogate of a post-mitotic tissue and showed that DdCBE delivered using AAV can install the desired mtDNA mutations in adult and neonatal mice. To the best of our knowledge, such a result has not been reported in the literature thus far. This work demonstrates that the DdCBE platform could be used for tissue-specific mtDNA mutagenesis in vivo and potentially for future therapies based upon somatic mitochondrial gene correction to treat mtDNA-linked mitochondrial diseases.

**Results**

**Design of DdCBE and mtDNA editing in mouse cultured cells.**

With the intention of testing the emerging mtDNA editing DdCBE technology, we set off to induce de novo mutations in mouse mitochondrial complex I in cultured cells and in somatic tissues upon AAV delivery. We aimed at editing the GGA glycine 40 codon in mouse MT-Nd3 (mtDNA positions: m.9576G and m.9577G) by targeting the complementary cytosine residues with DdCBE (Fig. 1a, C12 C13). To enable this, we designed four DdCBE pairs, containing TALE domains binding the mtDNA light (L) and heavy (H) strands (mtDNA positions m.9549–m.9564 and m.9584–m.9599, respectively) and different combinations of DdDAox splits (G1333 or G1397), targeting a 19 bp-long sequence in the mouse MT-Nd3 gene (mtDNA positions: m.9565–m.9583) (Fig. 1a-b) and named them DdCBE-Nd3-9577-1 to 4. The previous study has shown that for the sites containing two consecutive cytosines (preceded by a thymine), both of these cytosines can be edited by DdCBEs, with the following potential consequences: TCG-GGA > TTC-GAA, TCC-GGA > TTC-AGA, TCC-GGA > TTT-AA (edited C underlined)28. In line with this, we predicted three possible outcomes of m.9576G and m.9577G editing (Fig. 1b): [i] deamination of both complementary cytosines (Fig. 1b, C12, C13), would result in glycine to lysine mutation (G40K), [ii] deamination of C13 would lead to a glycine to glutamic acid mutation (G40E), whereas [iii] exclusive editing of C12 would lead to a premature AGA stop codon (G40*), according to the mitochondrial genetic code (Fig. 1b). The three predicted mutations are located in the conserved ND3 loop, involved in active/deactive state transition of complex I (Fig. 1c–d)31,32.

Next, we transiently delivered DdCBE-Nd3-9577 pairs into mouse cultured NIH/3T3 cells and selected the transfectants using fluorescence-activated cell sorting (FACS) at 24 h post-transfection and allowed for a 6 day-long recovery (Fig. 2a). After 7 days, we detected efficient editing of target cytosines by Sanger sequencing for the DdCBE-Nd3-9577 pairs 1, 2 and 3 (Fig. 2b). Although the targeted 19 bp sequence region between the TALE binding sites contained five cytosine residues with the correct thymine-cytosine (TC) consensus (Fig. 1a, C6, C12, C13, C17, and C18), positioning of the DdDAox deaminase domain allowed for editing of C12, C13 leading to the expected changes in the MT-Nd3 GGA glycine 40 codon (Fig. 2b). Next, we performed next-generation sequencing (NGS) analysis of the DdCBE-Nd3-9577-mediated mutagenesis to quantify the editing in each target cytosine and measure the proportion of editing resulting in the G40K, G40E, G40* mutations. This analysis revealed up to ~43% editing of C12 and C13 for DdCBE-Nd3-9577 pair 1, ~20–35% editing for pairs 2 and 3, and confirmed negligible editing activity of pair 4 (Fig. 2c). Furthermore, most of the NGS reads for pair 1 contained editing of both C12 and C13 translating to G40K mutation (~92.5%), whereas DNA reads corresponding to the
G40E and G40* changes constituted only ~4.5% and 3%, respectively (Fig. 2d). A similar editing pattern, but with a higher proportion of reads corresponding to G40E, was observed for pair 3 (G40K: ~83%, G40E: 14% G40* : 3%) (Fig. 2d). However, the mutagenesis pattern detected for pair 2 was skewed towards G40E, as compared to pairs 1 and 3, with reads corresponding to G40E accounting for 45.5% of C12 and C13-edited reads (G40K: ~53% and G40*: 1.5%) (Fig. 2d). The NGS analysis revealed a low level (below 3%) of C6 (mtDNA position m.9570 G) for pairs 1–3, which is predicted to install the E38K change (Fig. 2c). To confirm that the observed mtDNA editing is indeed a result of the catalytic activity of DddAtox, we used the DdCBE-Nd3-9577 pairs harboring a catalytically inactive DddAtox (E1347A) in a control transient transfection experiment. The NGS analysis showed that none of the catalytically inactive DdCBEs exerted detectable deamination activity that would lead to mtDNA editing, with the mutagenesis frequency being at the level of wild-type cells (Fig. 2c). Based on these in vitro results, we concluded that the DdCBE-Nd3-9577-1 pair is the most suitable for efficient installation of G40K and decided to proceed with in vivo experiments using this set.

**AAV-based in vivo DdCBE editing of mtDNA in adult mice.** To provide a proof-of-concept for in vivo mtDNA gene editing of somatic cells, we encapsidated the catalytically active and inactive versions of the DdCBE-Nd3-9577-1 monomers into the cardiotropic AAV9.45 serotype and administered them systemically via tail-vein injection at 1 × 10¹² viral genomes (vg) per monomer per 8-week-old adult mouse (Fig. 3a). At 3- and 24-weeks post-injection, we confirmed successful DdCBE DNA delivery to the cardiac tissue by quantitative PCR (Supplementary Fig. 1a-b) and detected its expression in total mouse heart tissue by western blotting (Supplementary Fig. 1c) and immunohistochemistry (Supplementary Fig. 1d-e). At 3 weeks after DdCBE-Nd3-9577-1 AAV injections, we detected low-level editing (1–2%) of the target C12 and C13 bases (corresponding to m.9576G > A and m.9577G > A) by NGS, but not by Sanger sequencing (Fig. 3b-c). The NGS analysis revealed C12 and C13 mutagenesis in the hearts of animals injected with catalytically active DdCBE-Nd3-9577, but not in those injected with a vehicle or catalytically inactive DdCBE, with the C12 and C13 editing pattern resembling the one observed in in vitro experiments (Fig. 3d). Notwithstanding, at 24-weeks post-injection robust editing (10–20%) of C12 and C13 was observed in the cardiac tissue of mice injected with catalytically active DdCBE-Nd3-9577-1 by Sanger sequencing and NGS, with no detectable changes being detected for vehicle and catalytically inactive controls (Fig. 3e-f). Further analysis confirmed that in the majority (94%) of the NGS reads both C12 and C13 were edited, translating into the G40K MT-ND3 mutation (Fig. 3g). We did not detect any adverse effect on mtDNA copy number in DdCBE AAV-transduced cardiac tissue as compared to vehicle-injected controls (Supplementary Fig. 1f-g). Taken together, these results established that DdCBE editing can be applied to install mtDNA mutations in vivo in post-mitotic tissues.

**AAV-based in vivo DdCBE editing of mtDNA in neonates.** Having established that de novo mutations can be installed in vivo in the post-mitotic tissue of adult mice following AAV-assisted DdCBE transduction, we set off to investigate whether transgene delivery to younger subjects could enhance the editing. To this end, we injected neonatal subjects (first 24 h of life) with DdCBE-Nd3-9577-1 AAV9.45 and its catalytically inactive version via temporal vein injection at 1 × 10¹² vg per monomer per animal (Fig. 4a).
Upon sacrificing the animals at 3-weeks post-injection, we confirmed successful DdCBE-Nd3-9577-1 AAV delivery (Supplementary Fig. 2a) and robust expression in the total mouse heart (Supplementary Fig. 2b-c). At this time-point we observed high efficiency of editing of mtDNA in mouse heart, with Sanger sequencing and NGS revealing 20–30% of C > T (G > A) changes of C12 and C13 in the DdCBE-Nd3-9577-1-targeted spacing region (Fig. 4b-c). No editing of these bases was observed in the control pups injected with a vehicle and the catalytically inactive DdCBE-Nd3-9577-1 AAVs (Fig.4c). The vast majority of NGS reads (95%) contained simultaneous edits of C12 and C13 (corresponding to m.9576 G > A (C12 > T12) and m.9577 G > A (C13 > T13) mutations, which translate to p.G40K change in MT-ND3. c The NGS analysis of the editing region in cells treated with different DdCBE splits. Bars represent the mean (n = 2). Source data are provided as a Source Data file. The mutagenesis frequency for the catalytically inactive versions is provided in the Source Data file. d The distribution of NGS reads containing m.9576 G (C12) or m.9577 G (C13) edits. The G40K reads contain both m.9576 G > A (C12 > T12) and m.9577 G > A (C13 > T13) mutations, G40E reads contain only the m.9577 G > A (C13 > T13) mutation, while G40* reads contain only the m.9576 G > A (C12 > T12) mutation. Source data are provided as a Source Data file.

Off-target editing by DdCBE in adult and neonatal mice followed AAV delivery. To score mtDNA-wide off-targeting in the mice, we analyzed mtDNA from hearts of vehicle-injected controls and mice injected with active or inactive versions of the DdCBE-Nd3-9577-1 pair. Vehicle-injected and catalytically inactive editor samples were used as a control in order to distinguish DdCBE-induced C:G-to-T:A single-nucleotide variants (SNVs) from natural background heteroplasmy. The average frequencies of mtDNA-wide off-target C:G-to-T:A editing by DdCBE-Nd3-9577-1 in the adult animals treated for 3 weeks were comparable to those of the vehicle-injected and catalytically inactive-DdCBE controls (0.026–0.046%) (Supplementary Fig. 3a). However, the adult mice treated with DdCBE-Nd3-9577-1 for 24 weeks showed ~7-fold higher average off-target editing frequency (0.22–0.30%) as compared with the controls (Supplementary Fig. 3a). We observed the highest off-target editing in the neonates treated with DdCBE-Nd3-9577-1, which was ~3-fold higher than the one observed for 24-week AAV-treated adult mice (Supplementary Fig. 3a). There was a positive correlation...
between on-target and off-target editing, with increased m.9576 G and m.9577 G modification being accompanied by higher levels of C:G-to-T:A SNVs (Supplementary Fig. 3b). Next, we tested off-target editing at nuclear pseudogenes, which are identical or share a high degree of sequence homology with mtDNA (nuclear mitochondrial DNAs, NUMTs). We did not observe editing beyond the background at the tested NUMTs, even though one of them was identical with the mtDNA on-target sites (Supplementary Fig. 4). This result is consistent with previous reports of exclusive mitochondrial localization of DdCBEs. Taken together, our data show that, while no detectable off-targeting is observed in nDNA upon AAV delivery of DdCBE, substantial off-targets are observed in mtDNA, especially when the on-target modification is also high. The latter result suggests that future development of DdCBE must focus on further improvement of the precision of this emerging tool.

**Discussion**

The discovery of a bacterial cytidine deaminase acting on double-stranded DNA (DdDA) led to the development of mitochondrial DdDA-derived cytosine base editors (DdCBEs), which is likely to revolutionize the field of mammalian mtDNA genetic modification. The DdCBE technology provides the potential to reverse engineer the mitochondrial genome in animal cells and...
eventually correct homo- and heteroplasmic pathogenic point mutations in mtDNA. Generation of novel animal models is now expected to proceed in an expedited fashion, either by DdCBE-mediated manipulation of Embryonic Stem (ES) cells, direct modification of mouse embryos or, as shown here, by somatic delivery. As with any emerging technologies, the DdCBE approach needs to be tested in multiple systems to validate its usefulness. Thus far, the versatility of DdCBes was shown by successfully base editing five mtDNA genes with efficiencies ranging between 5 and 50% in human cells in vitro. Further proof-of-concept exemplified the use of base editing in mouse embryos and reported successful germline transmission of DdCBE-induced mtDNA edits.

In the latter report, mutations in MT-Nd5, generated by delivering DdCBE mRNAs in mouse zygotes were maintained throughout development and differentiation. These mutations were successful transmitted to offspring (F1) with heteroplasmy levels of up to 26%, providing evidence that DdCBes can be used to generate mouse models with bespoke mtDNA mutations. In this study, we used somatic AAV delivery of DdCBes, providing a proof-of-concept for an alternative in vivo mtDNA mutagenesis means. The presented successful AAV-based mtDNA editing is also critical for in vivo proof-of-concept and insights into potential clinical translation to human somatic mitochondrial gene correction therapies to treat primary mitochondrial disease (PMD) phenotypes in worst-affected tissues. These future therapies could be crucial for mtDNA-associated PMDs, whose de novo genetics and hard-to-predict penetrance make preimplantation genetic diagnosis (PGD) screening difficult.

We predicted two possible issues that could prevent efficient mtDNA editing by DdCBes in vivo. [i] The editing of mitochondrial genomes with the current DdCBes involves inhibition of mitochondrial base excision repair (BER), to allow the retention of uracil in DNA (the result of cytosine deamination) and a sufficient level of active mtDNA replication allowing for the conversion of uracil into thymine. The efficacy of mitochondrial BER had not been fully investigated in vivo and it was possible that it operates at the level of preventing efficient DdCBE-mediated editing. [ii] Previous reports highlighted that mammalian mtDNA is replicated continuously even in post-mitotic cells, but whether its activity is sufficient to achieve successful editing by DdCBes was unknown. The successful mtDNA editing in mouse hearts reported here show that [i] the efficacy of BER operating in mouse heart does not lead to immediate excision of uracil in DNA, precluding efficient editing, and [ii] the level of mtDNA replication is high enough for fixing C-to-U deamination events into C-to-T mutations within 3 or 24 weeks after DdCBE treatment of neonatal or adult mice, respectively.

In neonates, our data also show that DdCBE administration earlier during development results in higher editing efficiency. A partial explanation for this finding could be that [i] at earlier vector administration, the greater AAV vector-to-cell ratio promoted higher transduction of the DdCBes in the neonate heart and [ii] the postnatal development of mouse cardiomyocytes involves substantial mtDNA replication leading to an almost 13-fold increase of mtDNA copy number during the first four weeks of postnatal life, increasing the probability of fixing C-to-U deamination events into C-to-T mutations. Considering future
therapeutic interventions based on DdCBE-mediated mtDNA correction, this observation may be encouraging in the context of those mitochondrial diseases with early-onset and a rapid progression, for which administration of potential therapies in adults would be inadequate. Nonetheless, further studies on the gene correction potential of AAV-delivered DdCBEs would be required in mtDNA-disease mouse models. However, none of the four currently available mouse models harboring pathogenic mtDNA point mutations is suitable for a DdCBE-mediated gene correction study either due to the nature of mutation (MT-Nd6: m.13997 G > A, MT-MK: m.7731 G > A, MT-TA: m.5024 C > T) or incompatible sequence context upstream of a T-to-C mutation (MT-CO1: m.6589 T > C). The latter means that, in addition to DdCBE-based approaches, the field should continue generating novel mouse mtDNA mutated mouse lines using the established, phenotype-first pipeline, as it can generate any mtDNA mutations (not only CG to TA offered by DdCBEs). Our results confirm the previous observation that each DdCAlox split edits the TC sites with a preference for specific windows in the spacing region. They also highlight that for any given target sequence, testing G1397 and G1333 splits in both orientations are required to achieve on-target editing. Here we demonstrate that the pair DdCBE-Nd3-9577-1 combining the G1333-C split in the TALE targeting the L-strand with G1333-N on the TALE targeting the H-strand produces more robust base editing of C132 and C131 located on the H-strand. Such observations fall in line with the previous reported preference of this split combination, which favors base editing of H-strand Cs present in the center of the editing window between the TALEs.

Our off-target editing analysis revealed that adult mice treated with DdCBE-Nd3-9577-1 for 24 weeks show ~0.25% of CG-to-TA SNV frequencies mtDNA-wide, which is higher than these reported previously for DdCBEs transiently expressed for 3 days in human cells, which ranged between ~0.05 to ~0.15% also. The CG-to-TA SNV off-target frequencies detected in the neonates injected with the active DdCBE-Nd3-9577-1 pair for 3 weeks were on average at ~0.8%, which was ~5 times higher than the least "precise" mitochondrial base editor reported by Mok et al. We attribute these differences to longer mtDNA-DdCBE exposure time (weeks vs days) in our experiments and conclude that further optimization of mitochondrial DdCBE concentration and specificity will be required, especially in long-term in vivo experiments.

In the present study MT-Nd3 G40K was installed to provide a proof-of-concept of somatic mtDNA editing. However, this mutation is located in the conserved ND3 loop involved in active/deactive state transition. It is expected that high G40K heteroplasmy will result in mitochondrial dysfunction by permanently locking complex I in active confirmation, which warrants further studies. In addition, it has been previously shown that targeting the reversible S-nitrosation of the neighboring ND3 residue C35 protects against ischaemia-reperfusion (IR) injury. In this line, the G40K mutant could be explored in the context of changes in expression of Cys39 in models of IR injury.

In conclusion, DdCBE is a promising tool for de novo mtDNA editing in post-mitotic tissue, which upon further research and optimization could be used to revert pathogenic mtDNA variants in patients affected with mitochondrial disease.

Methods

Ethics statement. All animal experiments were approved by the local Animal Welfare Ethical Review Body (AWERB) at the University of Cambridge and carried out in accordance with the UK Animals (Scientific Procedures) Act 1986 (Procedure Project Licence: P6620973A) and EU Directive 2010/63/EU.

Plasmid construction and viral vectors. The DdCBE architectures were used as reported in. A catalytically dead DdCAlox (E1347A) was used in the "inactive" control experiments. TALE arrays were designed using the Repeat Variable DiResidues (RVDs) containing NI, NG, NN, and HD, recognizing A, T, G, and C, respectively. To construct the plasmids used in the cell screen, all DdCBE ORFs were synthesized as gene blocks (GeneArt, Thermofisher) and cloned into pVax vectors downstream of a mitochondrial localization signal (MLS) derived from SOD2, using the 5’ KpnI and 3’ BglII restriction sites (Supplementary Sequences 1). Vector construction of DdCBEs intended for AAV production was achieved by PCR amplification of the transgenes to include 5’ NotI and 3’ BamHI sites, followed by inserting into a rAAV2-CMV backbone (Supplementary Sequences 2), previously reported in. The resulting plasmids were used to generate recombinant AAV2/9.45 viral particles at the UNC Gene Therapy Center, Vector Core Facility (Chapel Hill, NC).

Cell culture and transfections. NIH/3T3 cells (CRL-1658TM, American Type Culture Collection (ATCC)) were cultured at 37°C under 5% (vol/vol) CO2 and in complete Dulbecco’s Modified Eagle Medium (DMEM) (4.5 g/l glucose 2 mM glutamine, 110 mg/ml sodium pyruvate), supplemented with 10% calf bovine serum and 1% penicillin/streptomycin (all from Gibco). Mycoplasma tests in the culture medium were negative. The cell line was not authenticated in this study. For DdCBE pair screen, NIH/3T3 mouse cells plated in six-well tissue culture plates at a confluence of 70% were transfected with 3200 ng of each monomer (L and H), to a total of 6400 ng of plasmid DNA using 16 μl of FuGENE-HD (Promega), following manufacturer’s guidelines. After 24 h, cells were collected for Fluorescence-activated cell sorting (FACS) and sorted for GFP and RFP double-positive cells using a BD FACSMelodyTM Cell sorter. The collected double-positive cell suspensions were plated with similar volumes of vehicle buffer (1× PBS, 230 mM NaCl and 5% w/v D-sorbitol).

Genomic DNA isolation and Sanger sequencing of MT-Nd3 locus. NIH/3T3 mouse cells were collected by trypsinization, washed once in PBS, and resuspended in lysis buffer (1 mM EDTA, 1% Tween 20, 50 mM Tris (pH = 8)) with 200 μg/ml of protease K. Lysates were incubated at 56 °C with agitation (300 rpm) for 1 h, and then incubated 95 °C for 10 min before use in downstream applications. Genomic DNA from mouse heart samples (~50 mg) was extracted with a Maxwell® 16 Tissue DNA Purification Kit in a Maxwell® 16 Instrument (Promega), according to the manufacturer’s instructions.

For Sanger sequencing, the MT-Nd3 edited region was PCR-amplified with GoTaq G2 DNA polymerase (Promega) using the following primers: Mmu_Nd3_Fw: 5’- GCC GAG GCA GCA GAA GGA GTG GCC -3’, and Mmu_Nd3_Rv: 5’- GGG CTA GAG ATA GAA TTG TGA CTA GAA -3’. The PCR was performed with an initial heating step of 1 min at 95°C followed by 35 cycles of amplification (30 s at 95 °C, 30 s at 65 °C, 30 s at 72 °C), and a final step of 5 min at 72°C. PCR purification and Sanger sequencing were carried out by Source Bioscience (UK) with the Mmu_Nd3_Rv primer.

High-throughput targeted amplicon sequencing. Genomic DNA was extracted as described above. For high-throughput targeted amplicon resequencing of the MT-Nd3 region, a 15,781 bp fragment was first amplified by long-range PCR to avoid amplification of nuclear mtDNA pseudogenes (NUMTs), with PrimeSTAR GXL DNA polymerase (TAKARA) using the following primers: Long_R_MtuNd3_Fw: 5’- TAT TGT TTG GTC GAG GCT GGA -3’ and LongR_mtDNA_Fw: 5’- GGC CTA GAG ATA GAA TTG TGA CTA GAA -3’. The PCR was performed with an initial heating step of 1 min at 95°C followed by 10 cycles of amplification (10 s at 98 °C, 13 min at 68 °C), and a final step of 10 min at 72°C. All PCR reactions from this and the following steps were carried out using an AmpliTaq Gold (Roche, 5 U/μl) and purified long-range PCR reactions was amplified with primers containing an overhang adapter sequence, compatible with Illumina index and sequencing primers, in a 25 μl reaction, with Phusion™ Hot Start Flex 2X Master Mix (NEB, M0536) using the following primers: Nd3adapter_Fw: 5’- TCG TGG GCA GGG TCA GAT GTG TAT AAG CAG CAG TCC GCC CAA GGA GAG AGT -3’ and Nd3adapter_Rv: 5’- TCG TGG GCT GGT CAG TGG AGT TCA AAA ACC GCA GAG GTG -3’. PCR was performed with an initial heating step of 30 s at 98°C followed by 12 cycles of amplification (10 s at 98 °C, 15 s at 62.2 °C, 15 s at 72°C), and a final step of 5 min at 72°C. The indexed PCR was further purified using a Maxiprep kit (Invitrogen, XC-131-1096) according to the manufacturer’s instructions. The PCR was performed with an initial heating step of 30 s at 98°C followed by 6 cycles of...
amplification (30 s at 98 °C, 30 s at 55 °C, 30 s at 72 °C), and a final step of 5 min at 72 °C. Libraries were subjected to high-throughput sequencing using the Illumina MiSeq platform (PE75) and demultiplexed using the illumina miSeq manufacturer’s software.

For mtDNA-wide off-targets analysis, two overlapping long amplicons (8331 bp and 8605 bp) covering the full mtDNA molecule were amplified by long-range with PrimerSTAR GXL DNA polymerase (TAKARA) using the following primers: mmu_ND2_Fw 5’- TCT CCG TCG TAC GTA CAA ACC AC-3’; with mmu_NDS_Rv 5’- GCC TGA GTG GAT GAT AAC CA-3’ and mmu_ND2_Rv 5’- GTA CGA TGG TCG CAA GGA GTA TA-3’; with mmu_NDS_Fw5 ’- CCT CCC ACT GTA CAC CAC CA-3’. The PCR was performed with an initial heating step of 1 min at 94 °C followed by 20 cycles of amplification (30 s at 98 °C, 30 s at 60 °C, 9 min at 72 °C), and a final step of 5 min at 72 °C.

For nuclear DNA off-targets analysis, two regions with high homology to the MT-Nd3 targeted region were analyzed. A region with 100% identity in chromosome 1 was amplified by long-range with PrimerSTAR GXL DNA polymerase (TAKARA) using the following primers: G40K_NUMT100_Fw2: 5’- TGG CAC GCC GTG GAT AAG CG-3’; with G40K_NUMT100_Rv2: 5’- ACA CAC ACT AGA CAA CCA CCA-3’. The second region with 86% identity in polymerase (TAKARA) using the following primers: G40K_NUMT86_Rv1: 5’- TGT GGC TGA GGT GAG GAT AAG CA-3’; and mmu_ND2_Fw: 5’- GTA CGA CAC ACT AGA CAA CCA CCA-3’. The PCR was performed with an initial heating step of 1 min at 94 °C followed by 20 cycles of amplification (30 s at 98 °C, 30 s at 60 °C, 9 min at 72 °C), and a final step of 5 min at 72 °C. Tagmentation and the indexing PCR were performed using the Nextera XT Index Kit (Illumina, FC-131-1096) according to the manufacturer’s instructions and as described above. Libraries were subjected to high-throughput sequencing using the Illumina MiSeq platform (PE250) and demultiplexed using the Illumina miSeq manufacturer’s software.

### Immunoblotting of DdCBEs in mouse hearts

Heart samples (~50 mg) were homogenized in 200 µl of ice-cold RIPA buffer (150 mM NaCl, 0.1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) containing 1x CompleteTM mini EDTA-free Protein Inhibitor Cocktail (Roche, UK), using a gentleMACSTM dissociator. Homogenates were incubated on ice for 20 mins and then clear by centrifugation (20,000 x g for 20 min at 4 °C). Protein lysates (~20 µg) were mixed with 10 X NuPAGE sample reducing agent and 4X NuPAGE LDS sample buffer (Invitrogen), and incubated for 3 min at 55 °C. The boiled protein samples were then separated in a Bolt 4-12% Bis-Tris (Thermo Fisher) pre-cast gel and later transferred to a PVDF membrane using an iBlot 2 gel transfer system (Thermo Fisher), according to the manufacturer’s recommendations. The residual proteins that remained in the gel were removed using SartoriusSafeStain (Thermo Fisher) and used as a loading control. The membrane was blocked in 5% milk in PBS with 0.1% Tween 20 (PBS-T) for 1 h at room temperature (RT) and then incubated with either rat anti-HA-Tag antibody (Roche, 11867423001), 1:100 diluted in 5% milk in PBST or mouse anti-FLAG-M2-tag (Sigma–Aldrich, F3165), 1,200 diluted in 5% milk in PBST. Membranes were washed three times with PBS-T for 10 min at RT and then incubated with HRP-linked secondary antibodies, either anti-rat IgG (Cell Signaling, 7077 S) or anti-mouse IgG (Promega, W4021), 1:500 diluted in 5% milk in PBST. The membranes were washed another three times as before and imaged digitally with an Amersham Imager 680 blot and gel imager (GE Healthcare), upon incubation with Amersham ECL® Western Blotting Detection Reagents (GE Healthcare).

### Immunohistochemistry and microscopy

At sacrifice, mouse heart samples were frozen by immersion in isopentane cooled in liquid nitrogen. For immunohistochemistry analysis, heart samples were mounted in optimal cutting temperature compound (OCT) and sectioned on a cryostat at ~20 ºC to a thickness of 8 µm. Sections were fixed in 10% neutral buffered formalin (SIGMA, HT501128) at RT. After three washes in PBS, samples were permeabilized using 0.2% Triton X-100 in PBS for 15 min at RT, followed by three washes in PBS, and then blocked in 5% normal goat serum + 2% BSA in PBS for 1 h at RT. After three washes in PBS, samples were incubated with the rabbit anti-HA-Tag antibody (Cell Signaling, 3724) primary antibody 1:2000 in DAKO solution (Agilent, S3022) for 1 h at RT, followed by three additional washes in PBS. Sections were then incubated with goat anti-rabbit IgG (H + L) AlexaFluor diluted 1:300 in DAKO diluent solution 568 for 1 h at RT, washed three times in PBS and finally coveredslip with prolonged diamond antifade mountant with DAPI (Thermo Fisher, P39692). All confocal images were acquired using a Zeiss LSM880 microscope using identical acquisition parameters.

### Statistics

Graphical visualization of data and all statistical analyses were performed using GraphPad Prism software (version 8.0). All numerical data are expressed as mean ± standard error of mean (SEM). Ordinary one-way ANOVA with Dunnett’s test was used for multiple comparisons. Animals were randomized and no blinding to the operator was used.

### Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### Data availability

The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files, apart from proprietary scripts which are available upon request by contacting the authors. The NGS files generated in this study have been deposited in GEO: GSE148046. Source data are provided with this paper.

### Code availability

On and off-target effects from next-generation sequencing data were calculated with Varscan2, source code: https://github.com/jbleh/varscan2, written by Koboldt et al.45.

Received: 14 September 2021; Accepted: 21 January 2022; Published online: 08 February 2022.

### References

1. Vafai, S. B. & Mothu, K. V. Mitochondrial disorders as windows into an ancient organelle. Nature 491, 374–383 (2012).
2. Suomalainen, A. & Batterby, R. J. Mitochondrial diseases: the contribution of organelle stress responses to pathology. Nat. Rev. Mol. Cell Biol. 19, 77–92 (2018).
3. Rath, S. et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 49, D1541–D1547 (2021).
4. Gorman, G. S. et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann. Neurol. 77, 753–759 (2015).
5. Russell, O. M., Gorman, G. S., Lightowler, R. N. & Turnbull, D. M. Mitochondrial diseases: hope for the future. Cell 181, 188–188 (2020).

### NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-022-28358-w | www.nature.com/naturecommunications

8
Filograna, R., Mennuni, M., Alsina, D. & Larsson, N. G. Mitochondrial DNA copy number in human disease: the more the better? *FEBS Lett.* 595, 976–1002 (2021).

Stewart, J. B. & Chinnery, P. F. Extreme heterogeneity of human mitochondrial DNA from organelles to populations. *Nat. Rev. Genet.* 22, 106–118 (2021).

Gorman, G. S. et al. *Mammalian* mtDNA disease. *Nat. Rev. Dis. Prim.* 2, 16080 (2016).

Gammage, P. A., Moraes, C. T. & Minczuk, M. Mitochondrial genome engineering: the revolution may not be CRISPR-Ized. *Trends Genet.* 34, 101–110 (2018).

Sevivastava, S. & Moraes, C. T. Manipulating mitochondrial DNA heteropylasma by a mitochondrially targeted restriction endonuclease. *Hum. Mol. Genet.* 10, 3093–3099 (2001).

Tanaka, M. et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease Smal into mitochondria. *J. Biomed. Sci.* 9, 534–541 (2002).

Alexeev, M. F. et al. Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MELAS syndromes. *Gene Ther.* 15, 516–523 (2008).

Minczuk, M., Papworth, M. A., Miller, J. C., Murphy, M. P. & Klug, A. Development of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. *Nucleic Acids Res.* 36, 3926–3938 (2008).

Minczuk, M., Kolaisinska-Zwierz, P., Murphy, M. P. & Papworth, M. A. Construction and testing of engineered zinc-finger proteins for sequence-specific modification of mtDNA. *Nat. Protoc.* 5, 342–356 (2010).

Bacman, S. R., Williams, S. L., Pinto, M., Peralta, S. & Moraes, C. T. Specific elimination of mutant mitochondrial genomes in patient-derived cells by mitoTALENs. *Nat. Med.* 19, 1111–1113 (2013).

Gammage, P. A., Rorbach, J., Vincent, A. I., Rebar, E. J. & Minczuk, M. Mitochondrially targeted ZENs for selective degradation of pathogenic mitochondrial genomes bearing large-scale deletions or point mutations. *EMBO Mol. Med.* 6, 458–466 (2014).

Hashimoto, M. et al. MitoTALEN: A general approach to reduce mutant mtDNA loads and restore oxidative phosphorylation function in mitochondrial diseases. *Mol. Ther.* 23, 1592–1599 (2015).

Gammage, P. A. et al. Near-complete elimination of mutant mtDNA by iterative or dynamic dose-controlled treatment with mitoZENs. *Nucleic Acid Res.* 44, 7804–7816 (2016).

Yang, Y. et al. Targeted elimination of mutant mitochondrial DNA in MELAS-iPSCs by mitoTALENs. *Cell Res.* 26, 1691–1695 (2018).

Zekonyte, U. et al. Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo. *Nat. Commun.* 12, 3210 (2021).

Bacman, S. R., Williams, S. L., Duan, D. & Moraes, C. T. Manipulation of mtDNA heteropylasma in all striated muscles of newborn mice by AAV9-mediated delivery of a mitochondria-targeted restriction endonuclease. *Gene Ther.* 19, 1101–1106 (2012).

Bacman, S. R. et al. MitoTALEN reduces mutant mtDNA load and restores tRNA(Ala) levels in a mouse model of heteroplasmatic mtDNA mutation. *Nat. Med.* 24, 1696–1700 (2018).

Gammage, P. A. et al. Genome editing in mitochondria corrects a pathogenic mtDNA mutation in vivo. *Nat. Med.* 24, 1691–1695 (2018).

Zekonyte, U. et al. Mitochondrial targeted meganuclease as a platform to eliminate mutant mtDNA in vivo. *Nat. Commun.* 12, 3210 (2021).

Mok, B. Y. et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. *Nature* 583, 631–637 (2020).

Lee, H. et al. Mitochondrial DNA editing in mice with DddA-TALE fusion deaminases. *Nat. Commun.* 12, 1190 (2021).

Guo, J. et al. Precision modeling of mitochondrial diseases in zebrafish via DdCBE-mediated mtDNA base editing. *Cell Discov.* 7, 78 (2021).

Agip, A. A. et al. Cryo-EM structures of complex I from mouse heart mitochondria in two biochemically defined states. *Nat. Struct. Mol. Biol.* 25, 548–556 (2018).

Blaza, J. N., Vinothkumar, K. R. & Hirst, J. Structure of the deactive state of mammalian respiratory complex I. *Structure* 26, 312–319 e313 (2018).

Gross, N. J., Getz, G. S. & Rabinowitz, M. Apparent turnover of mitochondrial deoxyribonucleic acid and mitochondrial phospholipids in the tissues of the rat. *J. Biol. Chem.* 244, 1552–1562 (1969).

Silva Ramos, E. et al. Mitochondrial fusion is required for regulation of mitochondrial DNA replication. *PloS Genet.* 15, e1008085 (2019).

Stewart, J. B. Current progress with mammalian models of mitochondrial DNA disease. *J. Inherit. Metab. Dis.* 44, 325–342 (2021).

Kauppila, J. H. K. et al. A phenotype-driven approach to generate mouse models with pathogenic mtDNA mutations causing mitochondrial disease. *Cell Rep.* 16, 2980–2990 (2016).

Chouciani, E. T. et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. *Nat. Med.* 19, 753–759 (2013).

Krueger, F., James, F., Ewels, P., Auffanour, E. & Schuster-Boeckler, B. FelixKrueger/TrimGalore v0.6.7. *Zenodo* https://doi.org/10.5281/zenodo.5127899 (2021).

Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat. Methods* 9, 357–359 (2012).

Danecek, P. et al. Twelve years of SAMtools and BCFTools. *Gigascience* https://doi.org/10.1093/gigascience/giaa008 (2021).

Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. *Genome Res.* 22, 568–576 (2012).

Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. *EMBnet J.* 17, 10–12 (2011).

Flati, T. et al. HPC-REDTools: a novel HPC-aware tool for improved large scale RNA editing analysis. *BMC Bioinformatics* 21, 353 (2020).